Head-To-Head Contrast: Immutep (IMMP) versus Idera Pharmaceuticals (NASDAQ:IDRA)

Immutep (NASDAQ: IMMP) and Idera Pharmaceuticals (NASDAQ:IDRA) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, valuation, risk, dividends, analyst recommendations and institutional ownership.

Insider and Institutional Ownership

How to Become a New Pot Stock Millionaire

0.3% of Immutep shares are held by institutional investors. Comparatively, 36.6% of Idera Pharmaceuticals shares are held by institutional investors. 12.4% of Idera Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Analyst Recommendations

This is a summary of recent recommendations for Immutep and Idera Pharmaceuticals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immutep 0 0 2 0 3.00
Idera Pharmaceuticals 0 0 4 0 3.00

Immutep presently has a consensus target price of $5.00, suggesting a potential upside of 179.33%. Idera Pharmaceuticals has a consensus target price of $4.75, suggesting a potential upside of 189.63%. Given Idera Pharmaceuticals’ higher probable upside, analysts plainly believe Idera Pharmaceuticals is more favorable than Immutep.

Earnings and Valuation

This table compares Immutep and Idera Pharmaceuticals’ top-line revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Immutep $3.18 million 15.34 -$7.06 million N/A N/A
Idera Pharmaceuticals $900,000.00 393.62 -$65.98 million ($0.42) -3.90

Immutep has higher revenue and earnings than Idera Pharmaceuticals.

Risk and Volatility

Immutep has a beta of 1.26, indicating that its stock price is 26% more volatile than the S&P 500. Comparatively, Idera Pharmaceuticals has a beta of 2.35, indicating that its stock price is 135% more volatile than the S&P 500.


This table compares Immutep and Idera Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Immutep N/A N/A N/A
Idera Pharmaceuticals -7,315.30% -78.83% -71.32%


Idera Pharmaceuticals beats Immutep on 6 of the 11 factors compared between the two stocks.

About Immutep

Immutep Ltd, formerly Prima BioMed Ltd., is a biotechnology company. The Company is engaged in research, development and commercialization of licensed medical biotechnology. It is also focused on development of immunotherapeutic products. The Company operates through Cancer Immunotherapy segment. Its core technologies are based on the Lymphocyte-activation gene 3 (LAG-3) immune control mechanism, which is involved in regulation of the T cell immune response. Its product, IMP321, is in clinical development for the treatment of a range of cancer indications, such as Metastatic Breast Cancer. IMP321 is in Phase IIb trials for Metastatic Breast Cancer and is being studied in Phase I for the treatment of Metastatic Melanoma. The Company is also focused on development of other products, which include IMP701, an antibody for cancer, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer.

About Idera Pharmaceuticals

Idera Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of oligonucleotide therapeutics for oncology and rare diseases in the United States. The company uses two drug discovery technology platforms to design and develop drug candidates, including toll-like receptor targeting technology and nucleic acid chemistry technology. Its drug candidates include IMO-2125, an agonist that is in Phase III clinical trial in combination with ipilimumab and pembrolizumab for the treatment of anti-PD-1 refractory metastatic melanoma; and which is in Phase Ib monotherapy trial in multiple tumor types for the treatment of refractory solid tumors, as well as IMO-8400, an antagonist, which is in Phase II clinical trial for the treatment of dermatomyositis. The company is also developing IDRA-008 apolipoprotein C-III gene target for the treatment of familial chylomicronemia syndrome and familial partial lipodystrophy; nucleic acid chemistry compound for renal target; and IMO-9200 for treating non-malignant gastrointestinal disorders. In addition, it is developing drug candidates to turn off the messenger RNA associated with disease causing genes. Idera Pharmaceuticals, Inc. has collaboration and license agreement with GlaxoSmithKline Intellectual Property Development Limited to license, research, develop, and commercialize pharmaceutical compounds from its nucleic acid chemistry technology for the treatment of selected targets in renal disease; Abbott Molecular Inc. for the development of an in vitro companion diagnostic; and Merck & Co to research, develop, and commercialize vaccine products. The company was founded in 1989 and is based in Cambridge, Massachusetts.

Receive News & Ratings for Immutep Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immutep and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply